NDAINHALATIONSPRAY, METERED
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . In the airways, it exhibits pharmacological effects through inhibition of M 3 -receptors at the smooth muscle leading to…
Clinical Trials (4)
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Started Mar 2019
116,133 enrolled
Asthma
Specific Use-Result of Spiriva Respimat® in Asthmatics
Started Jul 2017
193 enrolled
Asthma
Specific Use-result Surveillance of Spiriva Respimat in Asthmatics
Started Jun 2015
359 enrolled
Asthma
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Started Jun 2008
1,280 enrolled
Pulmonary Disease, Chronic Obstructive
Loss of Exclusivity
LOE Date
Apr 16, 2031
62 months away
Patent Expiry
Apr 16, 2031
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7396341 | Oct 10, 2026 | Product | — |
| 9027967 | Mar 31, 2027 | Product | — |
| 7396341*PED | Apr 10, 2027 | — | |
| 9027967*PED | Sep 30, 2027 | — | |
| 7837235 | Mar 13, 2028 | Product | — |